Innocan Pharma Corporation Plans NYSE American Listing
HERZLIA, Israel and CALGARY, AB – Innocan Pharma Corporation (CSE: INNPF), a pioneering pharmaceutical technology firm, has expressed its strong intention to transition to the NYSE American. This anticipated move is expected to occur around the beginning of January, pending approval of its application for listing.
Concurrent Offering and Future Trading Details
As part of this strategic initiative, Innocan will conduct a concurrent offering of its securities, dependent on market conditions and regulatory approvals. The company aims to provide more detailed insights about this offering through future filings with relevant regulatory bodies.
Innocan’s common shares are currently trading on the OTC Markets' OTCQB and will continue to do so until just before the NYSE listing goes live. This seamless transition will ensure that stockholders remain informed, as trading will wrap up on the OTCQB right before the company's shares begin on the NYSE American. Notably, trading will also continue on the Canadian Securities Exchange under the ticker symbol "INNO."
Innovative Approach in Pharmaceuticals and Wellness
Innocan is not just focused on financial growth but is also dedicated to innovation in pharmaceuticals and wellness. The company has developed a cutting-edge CBD-loaded liposome drug delivery platform. This technology promises precise dosing, prolonged release, and controlled management of synthetic CBD use, catering especially to non-opioid pain relief methods. In the wellness sector, Innocan has built an impressive portfolio filled with high-performance self-care and beauty products, promoting healthier lifestyle choices.
This unique approach also includes operations through BI Sky Global Ltd., a 60% owned subsidiary focusing on advanced online sales strategies, aimed at reaching broader consumer markets efficiently.
Investor Contact Information and Resources
For more insights and updates involving Innocan Pharma Corporation, interested parties may contact the CEO, Iris Bincovich. The team remains dedicated to fostering communication and transparency, reinforcing the company’s commitment to its stakeholders.
Investors can expect to receive timely updates through official channels as Innocan progresses towards its NYSE American listing.
Frequently Asked Questions
What is Innocan Pharma Corporation's primary focus?
Innocan focuses on developing innovative drug delivery technologies and wellness products, including a CBD delivery system for pain management.
When will Innocan's shares officially start trading on NYSE American?
Innocan anticipates that its shares will begin trading on the NYSE American around early January, subject to approval.
How will the concurrent offering affect current shareholders?
The concurrent offering is planned to provide additional capital and support, without requiring existing shareholders to take action prior to the NYSE listing.
What does Innocan's product line include?
Innocan offers a range of CBD enhanced pharmaceuticals and high-performance self-care products aimed at promoting a healthier lifestyle.
How can investors stay informed about Innocan's developments?
Investors are encouraged to subscribe to notifications from the company through its official communication channels for the latest updates and filings.
